TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06329102

Intervention type: PROCEDURE
Intervention: Surgical access
Description: Complications by Clavien Dindo Number of lymph nodes. Disease free and Overall survival

Intervention type: PROCEDURE
Intervention: Surgical access
Description: Complications by Clavien Dindo Number of lymph nodes. Disease free and Overall survival

Intervention type: PROCEDURE
Intervention: Surgical access
Description: Complications by Clavien Dindo Number of lymph nodes. Disease free and Overall survival
Study: NCT04970654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somapacitan
Description: Somapacitan (0.16 mg/kg/week) will be administered subcutaneously (s.c.; under the skin) once weekly by PDS290 pen-injector. Somapacitan can be injected any time during the once weekly dosing day. The dose will be calculated based on the subject's current body weight.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norditropin®
Description: Norditropin® (0.034 mg/kg/day) will be administered s.c. once daily by FlexPro® pen-injector. Norditropin® should be injected daily in the evening. The dose will be calculated based on the subject's current body weight.
Study: NCT05233618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tagraxofusp
Description: inpatient on days 1-3 of cycles 1-4 and days 1-2 of additional cycles
Study: NCT06308666

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delefilcon A contact lenses
Description: Daily disposable silicone hydrogel contact lenses indicated for the optical correction of myopia and hyperopia
Study: NCT05751837

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lipopolysaccharide
Description: One tumor will be injected with 1 ug LPS (investigational drug) over approximately one minute
Study: NCT05844280

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BFR+NMES at therapeutic level
Description: This group will receive therapy with BFR+NMES devices used at settings that are deemed by prior studies to be therapeutic.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: BFR+NMES at sub therapeutic level
Description: This means that the BFR tourniquet and the NMES device will be at such low settings as to not create the treatment effect but subject will have the equipments on their thigh during exercise
Study: NCT05721170

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beta blocker
Description: Investigation on beta-blockers in TAVI and brief post-TAVI period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beta blocker
Description: Investigation on beta-blockers in TAVI and brief post-TAVI period.
Study: NCT06059989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab subcutaneous
Description: Mono and combination therapy group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab subcutaneous
Description: Mono and combination therapy group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunosuppressive Agents
Description: Combination group only
Study: NCT05980325

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nordic Walking
Description: A 12-week Nordic Walking exercise programme supervised twice weekly

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aquatic Exercise
Description: A 12-week water-based exercise training programme supervised twice weekly

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Functional Exercise Training
Description: A 12-week circuit-based exercise training programme supervised twice weekly
Study: NCT06286462

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cancer Tracking System (CATSystem)
Description: The CATSystem provider dashboard highlights patients with overdue services or those in need of outreach and sends automated, customized texts to support screening and treatment follow-up per national guidelines. Points of intervention and alerts include: cervical cancer screening and treatment counseling, initial and follow up cervical cancer screening per national guidelines, treatment for precancer and cancer, referral tracking and follow up. In addition, the CATSystem can securely store images of the cervix taken with colposcopes to allow for remote expert consultation if needed to correctly diagnose a patient or can be reviewed at clinical team meetings for input. Primary goals of the CATSystem are to increase rates of guideline-adherent cervical cancer screening/ rescreening and improve guideline-adherent treatment, referral, and follow-up rates of women with positive screens.
Study: NCT06644235

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Application
Description: Before DFU care, the patient was given an appropriate position and the materials (forceps, scalpel, sponge, pad, bandage, etc.) and the temperature of the 0.9% NaCl solution kept in the refrigerator for 24 hours were measured with an infrared thermometer (+4°C to +8°C) and taken to the treatment area. The solution was transferred to a 50 mL syringe in a sterile manner. The solution was instilled into the wound simultaneously with wound care (5-15 min).
Study: NCT05306158

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CC+ECIG Condition
Description: Participants will push CC- and ECIG-related pictures.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CC Condition
Description: Participants will push CC-related images and push and pull ECIG-related pictures equally often.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Condition
Description: Participants will pull and push CC- and ECIG-related pictures equally often.
Study: NCT06571019

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cool roof
Description: Cool roofs are a heat-reflecting material that can be applied to existing household roofing in the form of a liquid-applied membrane. Cool roofs work by increasing solar reflectance (the ability to reflect the visible wavelengths of sunlight, reducing heat transfer to the surface) and thermal emittance (the ability to radiate absorbed solar energy) thereby reducing the amount of heat transferred into the home.
Study: NCT05955885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flurbiprofen Oral Lozenge
Description: This commercially available, over-the-counter lozenge manufactured by Reckitt Benckiser contains flurbiprofen as the active ingredient and is registered for the short-term treatment of sore throat associated with upper respiratory tract infections in people over the age of 12 years.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Difflam
Description: This is a non-medicated, control lozenge that is the same flavour as the experimental lozenge that is marketed to help soothe dry, tickly throats while supporting the body's immune health.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 8.75 MG
Description: This commercially available, over-the-counter spray manufactured by Reckitt Benckiser contains flurbiprofen as the active ingredient and is registered for the short-term treatment of sore throat associated with upper respiratory tract infections in people over the age of 12 years. It requires 3 actuations of the spray to deliver the full 8.75 dose. Here, a low dose control can be delivered by only performing 1 actuation of the spray.

Intervention type: DRUG
Group type: OTHER
Intervention: Flurbiprofen 8.75 MG
Description: This commercially available, over-the-counter spray manufactured by Reckitt Benckiser contains flurbiprofen as the active ingredient and is registered for the short-term treatment of sore throat associated with upper respiratory tract infections in people over the age of 12 years. It requires 3 actuations of the spray to deliver the full 8.75 dose. Here, a low dose control can be delivered by only performing 1 actuation of the spray.
Study: NCT00547326

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: treated with osteopatic cranial techniques
Description: treated with osteopatic cranial techniques

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Treatment with placebo
Description: Treatment with placebo
Study: NCT06153589

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Musicotherapy
Description: Musicotherapy will be offered to patients who meet the eligibility criteria, and have been randomized to the experimental arm.~Patients will only be seen once during the study. Patients are placed in individual rooms. Hifi audio headphones (equipped with hygienic earcups) and a tablet equipped with the Music Care application will be offered to patients in the experimental group and the investigators will help them choose the style of music, which respects the U-shaped sequence.~The Music Care application has proven that the use of headphones allows the patient to be isolated and therefore to obtain less parasitic care. He will be told at the start of the session that he can ask to interrupt it if he wishes to communicate with the team, particularly regarding possible pain.~The musicotherapy session begins before the act of debridement (10 minutes before), lasts during the act (40 minutes maximum), and continues for 10 minutes after the end of the debridement.
Study: NCT05542589

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phenytoin phonophoresis
Description: Phenytoin phonophoresis for 5-10 minute sessions, three times per week and six weeks as a total period treatment.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham phenytoin phonophoresis
Description: Sham phenytoin phonophoresis for 5-10 minute sessions, three times per week and six weeks as a total period treatment.
Study: NCT06355518

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Immunonutrition
Description: This formula is enriched in arginine, nucleotides (RNA) and omega-3 fatty acids and provides, with the proposed therapeutic volume (2 units per day), 36 grams of protein and 682 kcal/day.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard Oral Nutritional Supplement
Description: This formula provides 38 grams of protein and 500 kcal/day with the proposed therapeutic volume.
Study: NCT05321342

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bullying Classroom Check-Up (BCCU)
Description: BCCU professional development (PD) modules will be provided to all staff in intervention schools as part of their standard, school-approved professional development practices to provide knowledge and awareness for bullying identification, prevention, and intervention. In addition, consented 3rd-5th grade teachers will participate in the BCCU intervention. The coaching follows the original Classroom Check-Up model (Reinke, Herman, \& Sprick, 2011), embedding 5 steps (i.e., assessment of the classroom, feedback to teacher, goal setting and plan, ongoing coaching and guided practice in the TeachLivE© mixed-reality simulator \[developed at the University of Central Florida \[UCF\]; Dieker, Hynes, Hughes, \& Smith, 2008\], and self-monitoring) and utilizing motivational interviewing (Miller \& Rollnick, 2012) to empower teacher practice change.
Study: NCT04959266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adavosertib
Description: Patients will receive a single dose of Adavosertib orally in arm A, B, and C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adavosertib
Description: Patients will receive a single dose of Adavosertib orally in arm A, B, and C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adavosertib
Description: Patients will receive a single dose of Adavosertib orally in arm A, B, and C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Patients will receive Itraconazole orally once daily for 7 days in arm A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Patients will receive Rifampicin orally once daily for 13 days in arm B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Patients will receive Omeprazole orally once daily for 5 days in arm C.
Study: NCT06655155

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Efgartigimod PH20 SC
Description: Subcutaneous efgartigimod PH20 SC given by prefilled syringe

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo PH20 SC
Description: Subcutaneous placebo PH20 SC given by prefilled syringe
Study: NCT05949268

Intervention type: DEVICE
Intervention: Small bowel capsule endoscopy
Description: Patients with gastrointestinal bleeding receive small bowel capsule endoscopy after bleeding could not be located in gastroscopy or colonoscopy.
Study: NCT05784545

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blueberry powder supplement
Description: The intervention in this study is 12 weeks of daily blueberry supplementation which is comprised of freeze-dried powdered whole blueberries i.e., blueberries with water removed.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin supplementation
Description: The intervention in this study is 12 weeks of daily maltodextrin supplement used to mimic the carbohydrate composition of whole blueberries.
Study: NCT06671782

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kegel exercises
Description: Kegel exercises without any formal training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic Floor Muscle Exercise Program with biofeedback
Description: Patients in the intervention arm will undergo PFME training with a physical therapist 2 times before surgery (4-6 weeks \[in person\] and 3-4 weeks \[in person\], before surgery) (within ±1 week is considered acceptable to avoid protocol violations). Patients in the intervention group will also undergo 2 PFME training sessions after surgery (3 weeks and 1.5 months after surgery).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: All patients will complete the Prostate Quality of Life Survey at baseline and at 1.5, 3, and 6 months after radical prostatectomy (within ±2 weeks is considered acceptable to avoid protocol violations). This is part of the standard of care for patients undergoing prostatectomy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: All patients will complete the Prostate Quality of Life Survey at baseline and at 1.5, 3, and 6 months after radical prostatectomy (within ±2 weeks is considered acceptable to avoid protocol violations). This is part of the standard of care for patients undergoing prostatectomy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interviews
Description: A qualitative interview with each of the 15 patients in the intervention group to obtain information about the patient's experience. The interview will last for 30-60 min and will be conducted at 3-6 months after prostatectomy, when the patient has completed all 4 physical therapy sessions. It will cover topics related to patient involvement, satisfaction, and activation.
Study: NCT05614544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK3486
Description: HSK3486 for induction of general anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK3486
Description: HSK3486 for induction of general anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol for induction of general anesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intralipid
Study: NCT05352607

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Description: Put the patient in comfort position as long sitting on bed with a supported back and a pillow under the forearm, clean the skin by alcohol swab, setup the parameter, put a gel on electrodes then placed the negative electrode (black wire) over biceps belly and positive electrode (red wire) 3 cm distally from negative electrode , turn on TENS device .~With increase the intensity gradually until patient feel a tingling sensation (no muscle contraction) and every 10 minutes ask patient about the feeling until complete 30 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy treatment
Description: Application of a hot pack for 20 minutes to enhance muscle flexibility and get overall spastic muscle relaxation. Anti-spastic muscles (elbow extensors) facilitation: tapping followed by movements (three sets of 15 repetitions per session). Hand weight-bearing with bodyweight (two 5-minute per session). Passive stretching of tight muscles (elbow flexors) is used (this must be a slow and gradual stretch for 20 seconds, followed by 20 seconds of rest, five times per session). Upper-limb active exercises should be done gradually. include (finger flexion and extension exercises, elbow and shoulder (three sets of 20 reps for each session).
Study: NCT05289986

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DELSTRIGO 100Mg-300Mg-300Mg Tablet
Description: Delstrigo (300 mg of tenofovir disoproxil fumarate equivalent to 245 mg of tenofovir disoproxil, 300 mg of lamivudine and 100 mg of doravirine~- TDF/3TC/DOR)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DELSTRIGO 100Mg-300Mg-300Mg Tablet
Description: Delstrigo (300 mg of tenofovir disoproxil fumarate equivalent to 245 mg of tenofovir disoproxil, 300 mg of lamivudine and 100 mg of doravirine~- TDF/3TC/DOR)
Study: NCT06726473

Intervention type: DIAGNOSTIC_TEST
Intervention: Wet Blood Gas Analyzer (ABL90)
Description: This group involves the use of the ABL90 wet blood gas analyzer for measuring arterial whole blood samples. The results obtained from the ABL90 analyzer will be compared with those obtained from the EG-i30 dry blood gas analyzer

Intervention type: DIAGNOSTIC_TEST
Intervention: Dry Blood Gas Analyzer (EG-i30)
Description: This group involves the use of the EG-i30 dry blood gas analyzer for measuring arterial whole blood samples. The results obtained from the EG-i30 analyzer will be compared with those obtained from the ABL90 wet blood gas analyzer.
Study: NCT06725043

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic ultrasound
Description: Pulsed therapeutic ultrasound (1 MHz , 50% duty cycle and intensity gradually increased till the patient felt a deqi sensation).Each point was stimulated by ultrasound for 5 minutes at bilateral acupuncture points of PC6, PC7, BL60 and KI1(3 times / week for 4 weeks).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo therapeutic ultrasound
Description: patients were received placebo therapeutic ultrasound at bilateral acupuncture points of PC6, PC7, BL60, and KI.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional physical therapy program
Description: Strengthing exercise, balance training, stretching exercises and home exercise program and education

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Traditional physical therapy program
Description: Strengthing exercise, balance training, stretching exercises and home exercise program and education
Study: NCT06725797

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: wound hygiene with hypothermal sulfurous water by packs
Description: GROUP A: After dressing removal, the wound is exposed. Sulphur thermal water at spring temperature (23°C) is applied for 20 minutes on the untreated wound by packs on non woven gauzes entirely covering the area. Eventually, if dried, gauzes are externally watered with additional sulphurous thermal water during the 20 minutes. After water application the wound follows the other 3 steps of the wound hygiene protocol: non viable tissue removal, edges reactivation and dressing. Non interactive dressings, just for wound moisture management, are used on cleaned wound/s. Dressing fixation, elastic bandages or off-load will be provided when required. the intervention will be repeated every 48 hours for both arms.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: wound hygiene with hypothermal sulfurous water by limb full immersion
Description: GROUP B: After dressing removal, the wound is exposed. Sulphur thermal water at spring temperature (23°C) is applied for 20 minutes on the untreated wound by limb full immersion in a limb tub. After the immersion, the wound follows the other 3 steps of the wound hygiene protocol: non viable tissue removal, edges reactivation and dressing. Non interactive dressings, just for wound moisture management, are used on cleaned wound/s. Dressing fixation, elastic bandages or off-load will be provided when required. the intervention will be repeated every 48 hours for both arms.
Study: NCT06727058

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemic flu H5 mRNA vaccine
Description: Pharmaceutical Form: Suspension for injection~Route of Administration: Intramuscular (IM)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemic flu H5 mRNA vaccine
Description: Pharmaceutical Form: Suspension for injection~Route of Administration: Intramuscular (IM)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemic flu H5 mRNA vaccine
Description: Pharmaceutical Form: Suspension for injection~Route of Administration: Intramuscular (IM)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical Form: Liquid solution for injection~Route of Administration: Intramuscular (IM)
Study: NCT06726395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penicillin G_1200mg
Description: benzylpenicillin preferred dosing 1gx4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cloxacillin
Description: cloxacillin 2gx4
Study: NCT06725862

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Retrolaminar Block (RLB)
Description: This intervention involves administering 0.25% bupivacaine (0.1 mL/kg) into the retrolaminar space at the L4 vertebral level using a 22-G insulated needle under ultrasound guidance in pediatric patients after induction of general anesthesia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caudal Block (CB)
Description: This intervention involves administering 0.125% bupivacaine (1 mL/kg, maximum 20 mL) into the sacral canal using a 22-G insulated needle under ultrasound guidance in pediatric patients after induction of general anesthesia.
Study: NCT06725901

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Web-Based Application
Description: The intervention involves the DIAGEN-IA platform, a diagnostic support tool designed to identify pediatric neurological diseases with a genetic basis. Using a Bayesian network model and integrating ontologies such as ORDO, HPO, and HOOM, DIAGEN-IA links phenotypic data entered by physicians to suggested diagnoses and tests. Pediatric neurologists will be trained to use the platform during a 12-month intervention. DIAGEN-IA allows clinicians to input clinical and diagnostic data, generating differential diagnoses and recommended tests, with results exportable in PDF for integration into medical records. Platform usage will be tracked, including login frequency, time spent, and evaluations performed.